Mergers & Acquisition Advisory

*Enterprise Value

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada, though the Company is in the process of winding-down its manufacturing operations in Varennes.

Mimi's Rock Corp. is an online dietary supplement and wellness company which market and sells its products under the Dr. Tobias, All Natural Advice and Maritime Naturals brand names. The Dr. Tobias brand features over 30 products, including the top-selling Colon 14-Day Cleanse and the #1 selling Omega 3 Fish Oil on Amazon.com. All Natural Advice and Maritime Naturals products focus on skin and beauty care. Products sold under the All Natural and Maritime Naturals brand names are made in Canada and registered with Health Canada and under the EU Cosmetics Act. All Natural Advice has been featured on BNN as a top selling skincare brand in Canada, and has been rated the #1 Beauty Brand on Amazon Canada for the past four years.

About RxPx Corp.
In the evolving digital health industry, a newly merged company is on a mission to help healthcare and transform lives. RxMx and Curatio, backed by private equity firm Pemba Capital Partners, have merged to form RxPx.

RxPx is positioned to become the global leader in patient management software for life sciences companies globally. The combined strengths of newly merged RxMx and Curatio will deliver next level solutions to transform the lives of patients, especially those on specialty therapies.

The name RxPx combines Rx for prescription medication and Px for patient experience. With a mission of No Patient Alone, RxPx provides an end to end workflow solution that reduces burden on doctors, and supports patients at scale. The merger comes at a time when health systems are collapsing, pharmaceutical companies are undergoing massive change, and patients are increasingly relying on digital options.

RxPx is used in over 100 countries, available in 15 languages and has been designed specifically for the privacy, security and compliance needs of healthcare. RxMx was started by doctors for doctors to support physician workflows through automated processes that increase speed and access to therapy. Curatio was started by patients for patients as a social health prescription, enabling any healthcare organization to easily deliver private, personalized social support, education, daily coaching and adherence tracking

About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

About Field Trip Health & Wellness Ltd.
Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Pillar5, based in Arnprior, Ontario, became in independent company in 2009 and is one of the primary North American CDMOs for the production of sterile ophthalmic solutions and for solid dose manufacturing (tablets, capsules, etc.). Pillar5 was the first CDMO to offer multi-dose preservative free manufacturing capabilities for the North American ophthalmic market and offers services ranging from formulation, product manufacturing and custom packaging to technical services.

For information: www.pillar5pharma.com.

MONTRÉAL, Jan. 5, 2022 /CNW Telbec/ - Searchlight Pharma Inc. ("Searchlight"), a Canada focused, Montréal-based specialty healthcare company focused on women's health, urogynecology, and urology, announced today that it has completed the acquisition of ERFA Canada 2012 Inc. ("ERFA"), a Montréal-based distributor of niche pharmaceutical products across Canada addressing a range of underserved medical indications.

"We are very excited to announce the acquisition of ERFA and to welcome their high performing team to the Searchlight family," said Mark Nawacki, President & CEO of Searchlight Pharma Inc. "ERFA's portfolio of 23 marketed brands is synergistic with our existing business, and we look forward to continuing ERFA's mission to provide access to important niche products to patients across the country. The combination of Searchlight and ERFA creates a compelling platform with attractive critical mass across products, business operations and infrastructure. We are very well positioned to continue to deliver on our growth strategy while providing dependability and value to Canadian customers and patients."

Searchlight was advised by Bloom Burton Securities Inc. (financial advisory), Ernst & Young LLP (strategy and transactions, tax advisory), and Davies Ward Phillips and Vineberg (legal advisory). ERFA was advised by PricewaterhouseCoopers Corporate Finance Inc. (financial advisory), Raymond Chabot Grant Thornton LLP and Deloitte LLP (tax advisory), and Dunton Rainville (legal advisory).

Details of the transaction were not disclosed.

iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement will result in the reverse takeover of the Company as defined in the policies of the TSX Venture Exchange ("TSXV") and the resulting entity will continue to operate in the life sciences industry under the name "Satellos Bioscience Inc." (the "Resulting Issuer").

Pursuant to the Financing, the Company issued 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million. Each Subscription Receipt will entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions, including without limitation, the completion of the Arrangement, and without payment of additional consideration, one common share of the Resulting Issuer (a "Resulting Issuer Share"). The proceeds from the Financing have been placed in escrow and, upon satisfaction of the escrow release conditions, will be used for research, development, and general corporate expenses of the Resulting Issuer.

The Resulting Issuer Shares issued in connection with the Financing will be subject to a hold period expiring 4 months and one day from the date of issuance in accordance with applicable Canadian securities laws. Additionally, in connection with the Financing, certain Resulting Issuer Shares issued to former shareholders of Satellos pursuant to the Arrangement will be subject to a lock-up agreement.

The Financing was led by Bloom Burton Securities Inc. and includes Richardson Wealth Ltd.

Acquisition of Seroquel XR by Dahlin Pharma and Cheplapharm.

Bloom Burton Securities Inc. acted as advisor to Dahlin Pharma.